Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Finance
  • Nyse
  • Stocks
  • Yacht Buyer
  • Banking
  • Music
ncarol.com

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
ncarol.com/10212254

Trending...
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

More on ncarol.com
  • Power Business Solutions Announces Joint Venture with EIG Global Trust to Deliver Data Center Financial Solutions
  • Scoop Social Co. Partners with Fairmont Hotels & Resorts to Elevate Summer Guest Experiences with Italian Inspired Gelato & Beverage Carts
  • Buildout Launches Native Email Marketing Feature, Expanding Its End-to-End CRE Platform
  • North Carolina Constitutional Economist, Laurie Thomas Vass, Improves Global Ranking on Social Science Research Network (SSRN)
  • New Saxophone Prize Honors Astronaut Ronald E. McNair, First To Play Sax In Space

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Investor Contact:

Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Best Personal Injury Law Firms 2025 - ELA Awards
  • Baruch Arcade Launches AI-Powered Gaming Platform on Solana, do I smell an airdrop?
  • Expert Law Attorneys 2025 Best Attorneys
  • Best Family Law Attorneys Of 2025 - ELA Awards
  • Best Criminal Defense Attorneys Of 2025 - ELA Awards
  • Tatt:Magic Introduces First-Ever Antimicrobial Cleansing Spray for New Tattoo Aftercare
  • Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • Play-Based STEM Pilot in Daycares Achieve 100% Student Fun and Major Gains in Confidence & Curiosity
  • Cherokee Historical Association Moves to Co-Directorship, Names New Executive Leaders
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • The Brave and the Rescued Honors LA Fire Department First Responders
  • Slick Cash Loan shares credit score tips for borrowers using bad credit loans
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude
  • UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Kintetsu And Oversee Announce New Partnership
  • Save 10 Percent Off KeysCaribbean's Newly Added Luxury Vacation Home in Marathon
_catLbl0 _catLbl1

Popular on ncarol.com

  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL) - 117
  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway - 114
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT - 107
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District - 102
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development

Similar on ncarol.com

  • UK Financial Ltd Lists MayaFund (MFUND) ERC-20 Token on CATEX Exchange Ahead of Planned ERC-3643 Upgrade
  • Roblox and Solsten Alliances; a Stronger Balance Sheet and Accelerated Growth Through AI, Gaming, and Strategic Partnerships for Super League: $SLE
  • Scoop Social Co. Partners with Fairmont Hotels & Resorts to Elevate Summer Guest Experiences with Italian Inspired Gelato & Beverage Carts
  • Building a $145M AI-Powered Marine Platform as Listings Surge, Global Expansion Begins, OTH Shares Trade at a Discount: Off The Hook YS (N Y S E: OTH)
  • Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Slick Cash Loan shares credit score tips for borrowers using bad credit loans
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute